According to a study, the inflammatory diseases like psoriasis and rheumatoid arthritis are generally not associated with a greater risk for contracting Covid-19, where therapeutics suppresses the immune system in such patients. It is said that they can continue taking their normal prescribed medicine further.
While according to some scientists, a group of patients is seen at higher risk for COVID-19 with immunosuppressed who are commonly disposed to upper respiratory infections like a common cold,or which may cause a runny nose, cough, and a sore throat.
Also, research state that a large number of patients with inflammatory diseases like psoriasis, eczema, and lupus are seen at a lesser risk for COVID-19 than the other patients, despite their weak immune system, says the Dermatology researchers from the Henry Ford Health System in the US.
A study published in the Journal of the American Academy of Dermatology is the first one in analyzing the connection between the immunosuppressive medications for skin diseases and its risk involved with COVID- 19 and its consequences.
Jesse Veenstra, a Henry Ford dermatologist, and the study’s lead author told, “If you require an immune suppressant medication for your condition to be well controlled, you should not be afraid to continue with the same medication during the pandemic as well”.
It is too noted by the researchers that there can be complications due to weak immune systems with some patients on medication during this pandemic, and there can be a higher risks related to COVID-19 because until now there was a very little acquaintance about managing such patients.
YOU MAY LIKE TO READ: Benefits Of Routine Childhood Vaccines Far Outweigh Risks Of Additional COVID-19 Transmission, Says Lancet Study
Recently there was the retrospective analysis conducted for 213 patients who were reported taking immunosuppressive medication for immune-mediated inflammatory disease. These were the patients who had been receiving immunosuppressive medication were being tested at least one month before being tested for COVID-19 between February 1 and April 18. And it was found that about 36 percent of 213 patients tested positive for COVID-19. They did not report any complications like being hospitalized or placed on a ventilator and showed a difference from the other patients.
So, the scientists concluded that they did not find any substantiation of immunosuppressive medication in patients tested positive or developed any serious disease after that.
The patients showed a lower chance of hospitalization who are prescribed a TNF alpha inhibitor which is a protein therapeutics part of a class of immunosuppressive agents.
“The patients who were on multidrug therapy regimens were at greater odds of being hospitalized than those taking a single medication. Adding to that more research is needed to fully explain this finding,” says Veenstra on the other hand.
Limiting the Boundaries, the scientists illustrated that being a single-center study, these results may not be easy for discriminated against other communities as well. And they believe that undertaking multiple medications may further suppress the patient’s immune system, making them more vulnerable to COVID-19.
However, Veenstra added, “Traditionally, you think of these medications putting you at higher risk for infection and with COVID-19 but this is a new type of pathogen, and no one knows how these medications affect your immune system’s ability to deal with the infection.”